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Leptin resistance is an important mechanism underlying the development and
maintenance of obesity and is thus regarded as a promising target of obesity
treatment. Plasminogen activator inhibitor 1 (PAI-1), a physiological inhibitor of tissue-
type and urokinase-type plasminogen activators, is produced at high levels in adipose
tissue, especially in states of obesity, and is considered to primarily be involved in
thrombosis. PAI-1 may also have roles in inter-organ tissue communications regulating
body weight, because PAI-1 knockout mice reportedly exhibit resistance to high fat diet
(HFD)-induced obesity. However, the role of PAI-1 in body weight regulation and the
underlying mechanisms have not been fully elucidated. We herein studied how PAI-1
affects systemic energy metabolism. We examined body weight and food intake of PAI-1
knockout mice fed normal chow or HFD. We also examined the effects of pharmacological
inhibition of PAI-1 activity by a small molecular weight compound, TM5441, on body
weight, leptin sensitivities, and expressions of thermogenesis-related genes in brown
adipose tissue (BAT) of HFD-fed wild type (WT) mice. Neither body weight gain nor food
intake was reduced in PAI-1 KO mice under chow fed conditions. On the other hand,
under HFD feeding conditions, food intake was decreased in PAI-1 KO as compared with
WT mice (HFD-WT mice 3.98 ± 0.08 g/day vs HFD-KO mice 3.73 ± 0.07 g/day, P =
0.021), leading to an eventual significant suppression of weight gain (HFD-WTmice 40.3 ±
1.68 g vs HFD-KO mice 34.6 ± 1.84 g, P = 0.039). Additionally, TM5441 treatment of WT
mice pre-fed the HFD resulted in a marked suppression of body weight gain in a PAI-1-
dependent manner (HFD-WT-Control mice 37.6 ± 1.07 g vs HFD-WT-TM5441 mice
33.8 ± 0.97 g, P = 0.017). TM5441 treatment alleviated HFD-induced systemic and
hypothalamic leptin resistance, before suppression of weight gain was evident. Moreover,
improved leptin sensitivity in response to TM5441 treatment was accompanied byin.org June 2020 | Volume 11 | Article 9431
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Frontiers in Pharmacology | www.frontiersincreased expressions of thermogenesis-related genes such as uncoupling protein 1 in
BAT (HFD-WT-Control mice 1.00 ± 0.07 vs HFD-WT-TM5441 mice 1.32 ± 0.05, P =
0.002). These results suggest that PAI-1 plays a causative role in body weight gain under
HFD-fed conditions by inducing hypothalamic leptin resistance. Furthermore, they
indicate that pharmacological inhibition of PAI-1 activity is a potential strategy for
alleviating diet-induced leptin resistance in obese subjects.Keywords: plasminogen activator inhibitor-1, obesity, leptin resistance, arcuate nucleus, food
intake, thermogenesisINTRODUCTION
An alarming increase in the number of obese subjects has become
a major public health concern worldwide in recent decades, since
obesity increases cardiovascular risks with increased prevalence of
diabetes, hyperlipidemia, and hypertension, collectively termed the
metabolic syndrome. Two key components determining body
weight are energy intake and energy expenditure (Yamada et al.,
2008). These components are regulated by inter-organ/tissue
communications (Katagiri et al., 2007). Adipokines constitute a
group of cytokines that are synthesized predominantly in adipose
tissues and participate in such metabolic communications (Abella
et al., 2017). Among these factors, leptin is produced in proportion
to body fat mass and is released into the bloodstream. Increased
circulating leptin typically reduces feeding and promotes energy
expenditure by targeting hypothalamic nuclei that are important
for energy homeostasis (Cui et al., 2017). Obesity, however, is
associated with leptin resistance, a state in which elevated
circulating leptin and exogenously delivered leptin are both less
effective in creating satiety and suppressing food intake (Liu et al.,
2015). Thus, on the basis of the pathophysiology underlying
obesity, alleviation of leptin resistance is a reasonable and long-
awaited therapeutic strategy for treating obesity, the anticipated
outcome of which would be normalization of energy metabolism
regulation. Despite long-standing research efforts, however, such
pharmacologic agents have yet to be developed.
Plasminogen activator inhibitor 1 (PAI-1) was primarily
identified as a physiological inhibitor of tissue-type and
urokinase-type plasminogen activators, though it may also have
roles in inter-organ/tissue communications as an adipokine. PAI-1
is produced in adipose tissue (Khandekar et al., 2011) and its levels
are elevated in both adipose tissues and the plasma of obese mice
and humans (Bodary, 2007). Intraperitoneal administration of PAI-
1 was reported to increase food intake during refeeding after a 24-h
fast (Kenny et al., 2013). In addition, transgenic mice overexpressing
PAI-1 in gastric parietal cells, which results in plasma PAI-1
elevation, reportedly show both hyperphagia and obesity (Kenny
et al., 2013). In high fat diet (HFD)-fed PAI-1 knockout (KO) mice,
reduced weight gain, decreased plasma leptin levels, and increased
energy expenditure (when divided by body weight) were observed
(Ma et al., 2004). Therefore, PAI-1 is suggested to participate in
body weight regulation by modulating leptin effects such as energy
intake and/or energy expenditure, but the pathophysiological
mechanisms whereby PAI-1 modulates leptin sensitivities and
energy metabolism have not as yet been elucidated.in.org 2TM5441 is a low molecular weight compound which was
previously confirmed to specifically and dose-dependently
inhibit PAI-1 (Boe et al., 2013). The known phenotypic effects
of TM5441 in vivo include protection against hypertension and
vascular senescence in Nw-nitro-l-arginine methyl ester (L-
NAME)-induced hypertensive mice (Boe et al., 2013),
prolongation of lifespan in klotho null mice (Eren et al., 2014),
and improved renal function and morphology in streptozotocin-
induced diabetic mice (Jeong et al., 2016). In addition, a recent
study demonstrated that TM5441 treatment exerted a
suppressive effect on body weight gain, when provided together
with HFD-feeding (Piao et al., 2016). Thus, PAI-1 inhibition by
TM5441 treatment is a potential preventive/therapeutic strategy
for obesity. However, the molecular mechanisms underlying the
actions of PAI-1 inhibitors in suppressing body weight gain
remain essentially unexplored.
In the present study, we, therefore, attempted to elucidate
how PAI-1 affects systemic energy metabolism employing both
PAI-1 KO mice and PAI-1 inhibitor-treated mice. We identified
a novel pathophysiological role of PAI-1 in aggravating leptin
resistance and demonstrated a novel therapeutic PAI-1 inhibitor
action exerted by alleviating HFD-induced leptin resistance.MATERIALS AND METHODS
Animals
C57BL/6J mice were purchased from Japan SLC (Shizuoka,
Japan). PAI-1 KO mice (background strain C57BL/6J; strain
name B6.129S2-Serpine1tm1Mlg/J; stock no. 002507) were
obtained from Jackson Laboratory (Bar Harbor, ME, USA).
Mice were housed under controlled temperature and humidity
conditions on a 12-h light, 12-h dark cycle. The animals were
housed individually and given standard laboratory diet (65%
carbohydrate, 4% fat, 24% protein) and water ad libitum unless
otherwise noted. All animal studies were conducted in accordance
with the institutional guidelines for animal experiments at
Tohoku University.
High Fat Diet
Two types of HFD were used in this study. A safflower oil-rich
HFD (Yamada et al., 2006) (32% safflower oil, 33.1% casein,
17.6% sucrose, and 5.6% cellulose) was purchased from Oriental
Yeast (Tokyo, Japan) and a lard-rich D12492 HFD (31.7% lard,June 2020 | Volume 11 | Article 943
Hosaka et al. PAI-1 Aggravates Obesity25.8% casein, 8.9% sucrose, and 6.5% cellulose) was purchased
from Research Diet (New Brunswick, NJ, USA). Both of these
HFD were purchased in powder form and then shaped into
pellets in our laboratory.
Preparation of TM5441
The inhibitory activity and specificity of TM5441 were
previously described in detail (Boe et al., 2013). TM5441 was
mixed with HFD powder, and then shaped into pellets. GivenFrontiers in Pharmacology | www.frontiersin.org 3that mice eat approximately 4 g of HFD per day (Figure 1E), 108
mg of TM5441 per 900 g of HFD were mixed together when the
mice were approximately 30 g each. This enabled the mice to
consume approximately 15 mg of TM5441 per kg body weight
per day. The TM5441 dosage was set at 15 mg/kg of body weight
because TM5441 treatment at a dose of 20 mg/kg of body weight
has been shown to suppress HFD-induced body weight gain
without exerting adverse effects (Piao et al., 2016). Control mice




FIGURE 1 | Time courses of body weight changes, food intake, and oral glucose tolerance tests in PAI-1 knockout (KO) mice fed chow or the safflower oil-rich high
fat diet (HFD). (A) Daily food intake of chow-KO and chow-WT mice from the 1st day through the 5th day of observation. Each bar represents the mean ± SE of n =
6 mice. (B) Body weight of chow fed PAI-1 KO mice (chow-KO) and wild-type (WT) control mice (chow-WT). Eight-week-old mice were weighed weekly. Each bar
represents the mean ± SE of n = 6 mice. (C) Daily food intake of chow-KO and chow-WT mice from the 71st day through the 75th day of observation. Each bar
represents the mean ± SE of n = 6 mice. (D) Body weight of safflower oil-rich high fat diet (HFD) fed PAI-1 KO mice (HFD-KO) and WT control mice (HFD-WT).
Eight-week-old mice were fed safflower oil-rich HFD and then were weighed weekly. Each bar represents the mean ± SE of n = 8 mice. (E) Daily food intake of HFD-
KO and HFD-WT mice from the 1st day through the 21st day of observation. Each bar represents the mean ± SE of n = 9 mice. (F) Average food intake of HFD-KO
and HFD-WT mice from the 1st day through the 21st day of observation. Each bar represents the mean ± SE of n = 9 mice. (G) Blood glucose levels and
(H) plasma insulin levels during oral glucose tolerance tests performed 21 days after the initiation of safflower oil-rich HFD feeding. Results are expressed as mean ±
SE of n = 8 mice. *P < 0.05 and **P < 0.01.June 2020 | Volume 11 | Article 943
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Experimental Procedure 1
Eight-week-old PAI-1 KO mice (chow-KO mice) and wild type
(WT) control mice (chow-WT mice) were fed the normal chow
diet and were weighed weekly. Daily food intake was measured
for 5 consecutive days from the 1st day and from the 71st day
of observation.
Experimental Procedure 2
Eight-week-old PAI-1 KO mice (HFD-KO mice) and WT
control mice (HFD-WT mice) were fed safflower oil-rich HFD
and were weighed weekly. Daily food intake was measured for 21
consecutive days from the 1st day of observation. Oral glucose
tolerance tests were performed on the 22nd day.
Experimental Procedure 3
Eight-week-old WT mice were fed safflower oil-rich HFD or
lard-rich HFD and were weighed weekly.
Experimental Procedure 4
Eight-week-old PAI-1 KO mice were fed lard-rich HFD for 2
weeks. They were then divided into two groups. The first group
was fed HFD mixed with TM5441 (HFD-KO-TM5441 mice),
while the second group continued to eat HFD without TM5441
(HFD-KO-Control mice). Mice were weighed weekly and
sacrificed on day 35 to remove the liver and WAT.
Experimental Procedures 5–10
Eight-week-old WT mice were fed lard-rich HFD for 2 weeks.
They were then divided into two groups. The first group was fed
HFD mixed with TM5441 (HFD-WT-TM5441 mice), while the
second group continued to eat the HFD without TM5441 (HFD-
WT-Control mice).
For experimental procedure 5, mice were weighed weekly.
Blood was collected on day 7 to measure plasma leptin levels.
Liver weight and WAT weight were measured on day 7 by using
another set of mice.
For experimental procedure 6, spontaneous locomotor
activities were measured on day 7.
For experimental procedure 7, oral glucose tolerance tests
were performed on day 35.
For experimental procedure 8, all mice were given a daily
intraperitoneal injection of either leptin (HFD-WT-TM5441-
Leptin mice and HFD-WT-Control-Leptin mice) or saline
(HFD-WT-TM5441-Saline mice and HFD-WT-Control-Saline
mice) on day 7. The injections were continued once daily for 4
more days until day 11. Body weight was measured both before
the injection on day 7 and 24 h after the injection on day 11.
For experimental procedure 9, all mice were fasted on day 7
for 24 h. On day 8, which was the day after the 24-h fast, mice
were given a single injection of either leptin or saline. Four hours
after this injection, the mice were sacrificed by decapitation to
remove the brain.
For experimental procedure 10, all mice were sacrificed on
day 7 to remove BAT.Frontiers in Pharmacology | www.frontiersin.org 4Blood Analysis
Blood samples, 30 µl per mouse, were collected by incision of the
tail vein with a lance. Blood was collected into 0.5 ml Eppendorf
tubes containing 0.2 ml of 0.5 M ethylenediaminetetraacetic acid
(EDTA) and then centrifuged for 15 min at 8,000 rpm at 4°C to
obtain plasma. Plasma leptin levels were determined with
enzyme linked immunosorbent assay (ELISA) kits (Morinaga
Institute of Biological Science, Yokohama, Japan) (Chiba et al.,
2016). Plasma, 5 ml per mouse, was used for measuring leptin by
ELISA. None of the samples required dilution for the assay. The
detection range of the kit was 0.4–25.6 ng/ml.
Oral Glucose Tolerance Tests
Blood glucose levels were assayed using a Glutestmint kit (Sanwa
Kagaku Kenkyusho, Nagoya, Japan) (Uno et al., 2006). Plasma
insulin levels were determined with ELISA kits (Morinaga
Institute of Biological Science, Yokohama, Japan) (Uno et al.,
2006). Plasma, 5 ml per mouse, was used for measuring insulin by
ELISA. None of the samples required dilution for the assay. The
detection range of the kit was 0.156–10 ng/ml. Mice that had
been fasted for 9 h during daylight hours were given glucose at a
dose of 2 g/kg body weight (Yamada et al., 2006). Blood glucose
and plasma insulin were measured both immediately before
administration and then again 15, 30, 60, 90, and 120 min
after glucose loading.
Locomotor Activity
Spontaneous locomotor activities of mice were analyzed with an
infrared activity monitor (Supermex; Muromachi Kikai, Tokyo,
Japan) as previously reported (Tsukita et al., 2012).
Histological Analysis
Livers and white adipose tissues (WAT) were removed, fixed
with 10% formalin and embedded in paraffin (Tsukita et al.,
2012). Tissue sections were stained with hematoxylin eosin (HE).
Adipocyte size was measured by the diameters of the adipocytes
in light-microscopy images (20×) (n = 50 adipocytes per section,
two sections per mouse) and analyzed using Keyence BZ-X710
Analyzer software. Experiments were carried out in a blinded
manner by masking the slide number and then conducting the
evaluation in a random order (Drareni et al., 2018).
Leptin Loading Tests
Leptin loading tests were carried out as previously described
(Tsukita et al., 2012) with slight modifications. To examine the
effects of leptin treatment on body weight change, mice were
given daily intraperitoneal administrations of leptin (5 mg/kg of
body weight; R&D Systems, Minneapolis, MN, USA) or saline
for 5 consecutive days. The leptin dosage was set at 5 mg/kg of
body weight, based on a previous report (Kabra et al., 2016). To
examine the effects of leptin treatment on hypothalamic
neuropeptide expressions, 24-h fasted mice were given a single
injection of either leptin (5 mg/kg of body weight) or saline, and
were then sacrificed by decapitation 4 h after the injection. Brains
were immediately frozen in isopentane with dry ice and stored
at −80°C until RNA purification.June 2020 | Volume 11 | Article 943
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Coronal cryostat sections (80 mm) of the hypothalamic arcuate
nucleus (ARC) were placed on PEN-coated slides (Leica
Microsystems, Wetzlar, Germany) (Tsukita et al., 2012). Laser
microdissection was carried out on a Leica AS LMD (Leica
Microsystems, Wetzlar, Germany) (Asai et al., 2017).
Immediately after microdissection, total RNA was purified
using an RNeasy Micro Kit (Qiagen, Valencia, CA, USA)
(Tsukita et al., 2017).RNA Purification and Quantitative
Real-Time PCR (qRT-PCR)
Complementary DNA was synthesized from 1 mg of total RNA
using a QuantiTect Reverse Transcription Kit (Qiagen) and was
evaluated using a real-time PCR quantitative system (Light
Cycler Quick System 350S; Roche Diagnostics, Mannheim,
Germany) (Takahashi et al., 2013). mRNA expression levels
were normalized against the levels of glyceraldehyde 3-
phosphate dehydrogenase (gapdh) for the hypothalamic ARC
and beta-actin for brown adipose tissue. The sequences of the
forward and reverse primers used were as follows: agouti-related
peptide (agrp), forward, 5′-CCAGAGTTCCCAGGTCTAAG-3′;
agrp , r ever se , 5 ′ -CGGTTCTGTGGATCTAGCA-3 ′ ;
neuropeptide y (npy), forward, 5′-GCTTGAAGACCCTTCCAT
TGGTG-3′; npy, reverse, 5′-GGCGGAGTCCAGCCTAGTGG-
3′; proopiomelanocortin (Pomc), forward, 5′-TCACCACGGAG
AGCAACCT-3′; Pomc, reverse, 5′-CAGCGGAAGTGACC
CATGA-3′; gapdh, forward, 5′-TGAAGGTCGGTGTGAACG-
3′ ; gapdh , reverse, 5′-CCATTCTCGGCCTTGACT-3′ ;
uncoupling protein 1 (ucp1), forward, 5′-TACCAAGCTGTGC
GATGT-3′; ucp1, reverse, 5′-AAGCCCAATGATGTTCAGT-3′;
peroxisome proliferative activated receptor gamma coactivator 1
alpha (pgc-1a), forward, 5′-ATACCGCAAAGAGCACGAG
AAG-3′; pgc-1a, reverse, 5′-CTCAAGAGCAGCGAAAGCGTC
ACAG-3′; type II iodothyronine deiodinase (dio2), forward, 5′-
ACTCGGTCATTCTGCTCAA-3′; dio2, reverse, 5′- AAGCC
CAATGATGTTCAGT-3 ′ ; ce l l death- inducing DNA
fragmentation factor alpha subunit-like effector A (cidea),
forward, 5′-ACTTCCTCGGCTGTCTCAATGT-3′; cidea,
reverse, 5′- TATCGCCCAGTACTCGGAGCAT-3′; PR domain
containing 16 (prdm16), forward, 5′-TGTACAGGCAGGCTAA
GAA-3′; prdm16, reverse, 5′-CCTGTGATGTTCAAGGAA-3′;
beta-actin, forward, 5′-GATGCCCTGAGGCTCTT-3′; and beta-
actin, reverse, 5′-TGTGTTGGCATAGAGGTCTTTAC-3′.Statistical Analysis
All values are expressed as mean ± SE. Data were compared
employing Student’s t test to examine the effect of one factor,
two-way ANOVA followed by Tukey’s test to examine the effects
of two factors, or two-way repeat measures ANOVA to
determine variance with respect to time and mouse group. The
level of significance was set at P < 0.05.Frontiers in Pharmacology | www.frontiersin.org 5RESULTS
PAI-1 Deficiency Alleviates HFD-Induced
Body Weight Gain
We first examined the effects of PAI-1 deficiency on body weight and
food intake under normal chow feeding conditions (Experimental
procedure 1). Eight-week-old PAI-1 KO mice (chow-KO mice) and
wild type (WT) control mice (chow-WT mice) were fed the normal
chow diet. Daily food intake from the 1st day (Figure 1A) of
observation was similar in these two groups. Body weight of the
two groups were similar throughout the observation period
(Figure 1B), as expected from a previous report (Ma et al., 2004).
Daily food intake from the 71st day (Figure 1C) of observation was
also similar in these two groups. Therefore, PAI-1 deficiency itself
appears to have almost no effects on either eating habits or body
weight alterations under normal chow feeding conditions.
We next examined the effects of PAI-1 deficiency on body
weight and food intake under HFD-fed conditions. Safflower oil-
rich HFD was given to 8-week-old PAI-1 KO mice (HFD-KO
mice) and WT mice (HFD-WT mice) (Experimental procedure
2). The HFD-KO mice gained less weight than the HFD-WT
mice (Two-way repeat measures ANOVA; F = 4.53, P < 0.001,
HFD-WT mice 40.3 ± 1.68 g vs HFD-KO mice 34.6 ± 1.84 g, P =
0.039), and the difference between the two groups became
statistically significant after 106 days (Figure 1D). Strikingly,
HFD-KO mice ate significantly less than HFD-WT mice before
their body weights showed significant differences (Two-way
repeat measures ANOVA; F = 35.89, P < 0.001) (Figure 1E)
and the average food intake amounts during the experimental
period (21 days) were also significantly smaller in HFD-KO mice
than in HFD-WT mice (HFD-WT mice 3.98 ± 0.08 g/day vs
HFD-KO mice 3.73 ± 0.07 g/day, P = 0.021) (Figure 1F). Since
reduced food intake preceded the evident differences in body
weight, reduced energy intake is likely to be a direct cause, rather
than a result, of suppressed weight gain. Thus, PAI-1 deficiency
may suppress HFD-induced weight gain, while exerting minimal
effects on weight regulation under normal chow-fed conditions.
PAI-1 Deficiency Improves Insulin
Sensitivities and Insulin Secretion
We next performed oral glucose tolerance tests on HFD-KO
mice and HFD-WT mice after 22 days of HFD feeding. Blood
glucose levels of HFD-KO mice tended to be decreased as
compared to those of HFD-WT mice (Figure 1G). Fasting
plasma insulin levels were significantly lower in HFD-KO mice
despite fasting blood glucose levels being similar (Two-way
repeat measures ANOVA; F = 5.17, P = 0.036, HFD-WT mice
0.69 ± 0.03 ng/ml vsHFD-KOmice 0.52 ± 0.04 ng/ml, P = 0.005)
(Figure 1H), indicating that these mice had better insulin
sensitivity. In addition, plasma insulin levels 15 min after
glucose loading were significantly higher in HFD-KO mice
than in HFD-WT mice (HFD-WT mice 1.33 ± 0.09 ng/ml vs
HFD-KO mice 1.65 ± 0.11 ng/ml, P = 0.048). Taken together,
these results suggest that suppression of body weight gain inJune 2020 | Volume 11 | Article 943
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stimulated secretion of insulin.
PAI-1 Inhibitor Treatment Alleviates
HFD-Induced Body Weight Gain and
Insulin Resistance
We then examined the effects of TM5441, a selective PAI-1
inhibitor, on body weight in HFD-fed mice. In the following
experiments, we switched from safflower oil-rich HFD to lard-richFrontiers in Pharmacology | www.frontiersin.org 6HFD (Experimental procedure 3), because mice fed the latter
gained more weight than those given the former (Two-way repeat
measures ANOVA; F = 12.38, P < 0.001, lard-rich HFD mice
41.5 ± 1.21 g vs safflower oil-rich HFD mice 34.1 ± 0.98 g on day
49, P = 0.003) (Figure 2A). Ten-week-old WT mice that had been
pre-fed a lard-rich HFD for 2 weeks were divided into two groups.
The first group was then fed HFD mixed with TM5441 (HFD-
WT-TM5441 mice), while the second group continued to eat the




FIGURE 2 | Body weight and oral glucose tolerance tests in lard-rich HFD fed mice treated with TM5441. (A) Body weight of WT mice fed safflower oil-rich HFD or
lard-rich HFD. Each bar represents the mean ± SE of n = 5 mice. (B) Body weight of lard-rich HFD-fed mice treated with TM5441. Ten-week-old WT mice that had
been pre-fed the lard-rich HFD for 2 weeks were given either lard-rich HFD mixed with TM5441 (HFD-WT-TM5441 mice) or lard-rich HFD (HFD-WT-Control mice)
and then were weighed weekly. Each bar represents the mean ± SE of n = 10 mice. (C) Liver weight of HFD-WT-TM5441 and HFD-WT-Control mice. Each bar
represents the mean ± SE of n = 9 mice. (D) Representative hematoxylin eosin (HE) staining of liver sections of HFD-WT-TM5441 and HFD-WT-Control mice (original
magnification: 20×, scale bars: 100 mm). (E) Epididymal white adipose tissue (WAT) weight of HFD-WT-TM5441 and HFD-WT-Control mice. Each bar represents the
mean ± SE of n = 9 mice. (F) Representative HE staining of WAT sections of HFD-WT-TM5441 and HFD-WT-Control mice (original magnification: 20×, scale bars:
100 mm). (G) Adipocyte size of HFD-WT-TM5441 and HFD-WT-Control mice. Each bar represents the mean ± SE of n = 9 mice. (H) Locomotor activities of HFD-
WT-TM5441 and HFD-WT-Control mice during light hours and dark hours. Each bar represents the mean ± SE of n = 7 mice. (I) Blood glucose levels and
(J) plasma insulin levels during oral glucose tolerance tests performed 35 days after the initiation of lard-rich HFD feeding. Results are expressed as mean ± SE of
n = 9 mice. *P < 0.05 and **P < 0.01.June 2020 | Volume 11 | Article 943
Hosaka et al. PAI-1 Aggravates Obesityprocedure 5). No death, hair loss, signs of respiratory infections
such as open-mouth breathing, or other adverse effects were
observed in any of the TM5441 treated mice. Body weight gain
was slower in mice that ate HFD mixed with TM5441, and these
reductions reached statistical significance 35 days after the
initiation of inhibitor treatment (Two-way repeat measures
ANOVA; F = 5.24, P < 0.001, HFD-WT-Control mice 37.6 ±
1.07 g vs HFD-WT-TM5441 mice 33.8 ± 0.97 g on day 35, P =
0.017) (Figure 2B). Liver weights on day 7 were similar in the two
groups (Figure 2C), and there was no evidence of either
hepatocyte ballooning or lobular inflammation in the two
groups (Figure 2D). On the other hand, epididymal white
adipose tissue (WAT) weight on day 7 was significantly lower in
HFD-WT-TM5441 mice than in HFD-WT-Control mice (HFD-
WT-Control mice 0.98 ± 0.08 g vsHFD-WT-TM5441 mice 0.63 ±
0.06 g, P = 0.003) (Figure 2E). On average, adipocytes were
markedly smaller in HFD-WT-TM5441 mice (HFD-WT-Control
mice 71.05 ± 1.49 mm vs HFD-WT-TM5441 mice 60.35 ± 2.89
mm, P = 0.003) (Figures 2F, G), indicating decreased
accumulation of lipid per adipocyte in HFD-WT-TM5441 mice.
Thus, TM5441 treatment alleviates the weight gain induced by
HFD, after reducing WAT weight. If loss of lean muscle mass had
occurred, it might also have contributed to reduced body weight
gain. Although direct measurement of lean muscle mass will be
required to examine this possibility, spontaneous locomotor
activities on day 7, during both light hours and dark hours, were
similar in these groups of mice (light hours: HFD-WT-Control
mice 25.68 ± 1.81 counts/min vsHFD-WT-TM5441 mice 25.56 ±
2.76 counts/min, P = 0.972, dark hours: HFD-WT-Control mice
96.88 ± 2.93 counts/min vsHFD-WT-TM5441 mice 90.06 ± 10.53
counts/min, P = 0.544) (Figure 2H) (Experimental procedure 6),
which might suggest that severe loss of muscle mass would have
been unlikely to have occurred in HFD-WT-TM5441 mice.
Next, HFD-WT-TM5441 mice and HFD-WT-Control mice
were subjected to oral glucose tolerance tests on day 35
(Experimental procedure 7). Blood glucose levels of HFD-WT-
TM5441 mice tended to be lower than those of HFD-WT-Control
mice (Figure 2I). Plasma insulin levels were significantly decreased
in HFD-WT-TM5441 mice as compared to HFD-WT-Control
mice (Two-way repeat measures ANOVA; F = 5.17, P = 0.036, 0
min: 1.43 ± 0.14 ng/ml vs 0.98 ± 0.09 ng/ml, P = 0.017, 30 min:
2.35 ± 0.28 ng/ml vs 1.40 ± 0.19 ng/ml, P = 0.015, 60 min: 1.34 ±
0.12 ng/ml vs 0.85 ± 0.11 ng/ml, P = 0.007, 90 min: 1.47 ± 0.14 ng/
ml vs 1.01 ± 0.10 ng/ml, P = 0.021, HFD-WT-Control mice vs
HFD-WT-TM5441 mice, respectively) (Figure 2J). These results
suggest that insulin sensitivity of HFD-WT-TM5441 mice is
increased as compared to that of HFD-WT-Control mice.
Taken together, these results indicate that pharmacological
inhibition of PAI-1 activity after initiation of HFD feeding
attenuates body weight gain and improves insulin sensitivity.HFD-Induced Body Weight Gain Is
Attenuated by TM5441 Treatment Through
a PAI-1 Dependent-Mechanism
To rule out the possibility that body weight reduction seen in
HFD-WT-TM5441 mice (Figure 2B) was a consequence of non-Frontiers in Pharmacology | www.frontiersin.org 7specific effects of TM5441, i.e. effects other than PAI-1
inhibition, such as an unpleasant taste, we treated HFD-fed
PAI-1 KO mice with TM5441 (Experimental procedure 4).
Ten-week-old PAI-1 KO mice that had been pre-fed HFD for
2 weeks were divided into two groups. The first group was then
fed HFD mixed with TM5441 (HFD-KO-TM5441 mice), while
the second group continued to eat HFD without TM5441 (HFD-
KO-Control mice). As expected, weekly body weights of HFD-
KO-TM5441 mice after TM5441 loading were almost equal to
those in HFD-KO-Control mice (Figure 3A). In addition, not
only liver but also epididymal WAT weights on day 35 were
similar in the two groups (Figures 3B, C). Thus, anti-obesity
effects of TM5441 treatment in HFD-fed mice were observed
only in the presence of intrinsic PAI-1 (Figure 2B). Thus,
TM5441 was confirmed to exert its anti-obesity effects via
inhibition of PAI-1 activity. In addition, these findings clearly
indicate that treatment with a PAI-1 inhibitor after obesity
development is also effective for suppressing weight gain in
mice that are not depleted of PAI-1.
PAI-1 Inhibitor Treatment
Improves Leptin Sensitivity
Leptin functions as an afferent signal in a negative feedback loop
of energy metabolism leading to reduced feeding and promotion
of energy expenditure (Friedman, 2016). However, hypothalamic
leptin sensitivity is known to be impaired despite elevated
circulating leptin concentrations under conditions of obesity
(Cui et al., 2017), a phenomenon regarded as leptin resistance.
Leptin resistance is considered to further promote body weight
gain through a feed-forward system (Yamada et al., 2013).A
B C
FIGURE 3 | Body weight of lard-rich HFD fed PAI-1 knockout (KO) mice
treated with TM5441. (A) Body weight of lard-rich HFD-fed PAI-1 KO mice
treated with TM5441. Ten-week-old PAI-1 KO mice that had been pre-fed
the lard-rich HFD for 2 weeks were given either lard-rich HFD mixed with
TM5441 (HFD-KO-TM5441 mice) or lard-rich HFD (HFD-KO-Control mice)
and then were weighed weekly. Each bar represents the mean ± SE of n = 9
mice. (B) Liver weight of HFD-KO-TM5441 and HFD-KO-Control mice. Each
bar represents the mean ± SE of n = 9 mice. (C) WAT weight of HFD-KO-
TM5441 and HFD-KO-Control mice. Each bar represents the mean ± SE of
n = 9 mice.June 2020 | Volume 11 | Article 943
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TM5441 mice and HFD-WT-Control mice 1 week after TM5441
loading (Experimental procedure 5). At this time-point, although
body weights were similar in the two groups (day 7 of
Figure 2B), interestingly, plasma leptin levels in HFD-WT-
TM5441 mice had already decreased to less than half of those
in HFD-WT-Control mice (HFD-WT-Control mice 8.38 ± 1.13Frontiers in Pharmacology | www.frontiersin.org 8ng/ml vs HFD-WT-TM5441 mice 3.37 ± 0.68 ng/ml, P = 0.002)
(Figure 4A). In addition, during the following weeks, HFD-WT-
TM5441 mice gained less body weight than HFD-WT-Control
mice. Therefore, we hypothesized that TM5441 treatment
alleviated leptin resistance under HFD-fed conditions. To
examine this possibility, we administered exogenous leptin to




FIGURE 4 | Evaluation of leptin sensitivity in lard-rich HFD fed mice treated with TM5441. (A) Plasma leptin levels of HFD-WT-TM5441 mice and HFD-WT-Control
mice. Results are expressed as mean ± SE of n = 9 mice. (B) Body weight of HFD-WT-TM5441-Leptin mice, HFD-WT-Control-Leptin mice, HFD-WT-TM5441-Saline
mice, and HFD-WT-Control-Saline mice. Ten-week-old WT mice that had been pre-fed the lard-rich HFD for 2 weeks were given either lard-rich HFD mixed with
TM5441 or lard-rich HFD for 1 week. Results are expressed as mean ± SE of n = 4 mice. (C) Body weight changes during leptin treatment. Mice were given a daily
intraperitoneal injection of either leptin (HFD-WT-TM5441-Leptin mice or HFD-WT-Control-Leptin mice) or saline (HFD-WT-TM5441-Saline mice or HFD-WT-Control-
Saline mice) for 5 consecutive days. Body weight immediately before the first leptin injection was subtracted from body weight 24 h after the last injection. Results are
expressed as mean ± SE of n = 4 mice. (D) Body weight of HFD-WT-TM5441-Leptin mice, HFD-WT-Control-Leptin mice, HFD-WT-TM5441-Saline mice, and HFD-
WT-Control-Saline mice. Ten-week-old WT mice that had been pre-fed the lard-rich HFD for 2 weeks were given either lard-rich HFD mixed with TM5441 or lard-rich
HFD for 1 week. Results are expressed as mean ± SE of n = 4 mice. (E) Relative mRNA expressions of agouti-related peptide (agrp), neuropeptide y (npy), and
proopiomelanocortin (Pomc) in the hypothalamic arcuate nucleus (ARC). Mice were fasted for 24 h and then given a single intraperitoneal injection of either leptin (HFD-
WT-TM5441-Leptin mice or HFD-WT-Control-Leptin mice) or saline (HFD-WT-TM5441-Saline mice or HFD-WT-Control-Saline mice). Brain samples were harvested 4 h
after the injection. Results are expressed as mean ± SE of n = 4 mice. (F) Relative mRNA expressions of uncoupling protein 1 (ucp1), peroxisome proliferative activated
receptor gamma coactivator 1 alpha (pgc-1a), type II iodothyronine deiodinase (dio2), cell death-inducing DNA fragmentation factor alpha subunit-like effector A (cidea),
and PR domain containing 16 (prdm16) in brown adipose tissue (BAT). Ten-week-old WT mice that had been pre-fed the lard-rich HFD for 2 weeks were given either
lard-rich HFD mixed with TM5441 or lard-rich HFD for 1 week. Results are expressed as mean ± SE of n = 9 mice. *P < 0.05 and **P < 0.01.June 2020 | Volume 11 | Article 943
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mice were given a daily intraperitoneal injection of either leptin
(HFD-WT-TM5441-Leptin mice and HFD-WT-Control-Leptin
mice) or saline (HFD-WT-TM5441-Saline mice and HFD-WT-
Control-Saline mice) for 5 consecutive days. There were no
differences in body weights between the mice group before the
first day of leptin or saline injection (Figure 4B). Under these
settings, no differences in body weight change after leptin or
saline injection were seen between HFD-WT-Control-Saline
mice and HFD-WT-Control-Leptin mice (Figure 4C),
suggesting that these HFD-fed mice have severe leptin
resistance. Interestingly, administration of leptin after TM5441
treatment resulted in a remarkable suppression of body weight
gain; HFD-WT-TM5441-Leptin mice gained markedly less
weight than any of the other groups (HFD-WT-Control-Saline
mice 1.70 ± 0.34 g vsHFD-WT-TM5441-Leptin mice 0.06 ± 0.38
g, P = 0.013, HFD-WT-Control-Leptin mice 1.55 ± 0.70 g vs
HFD-WT-TM5441-Leptin mice 0.06 ± 0.38 g, P = 0.030, HFD-
WT-TM5441-Saline mice 1.32 ± 0.31 g vs HFD-WT-TM5441-
Leptin mice 0.06 ± 0.38 g, P = 0.049) (Figure 4C). Because body
weights of all four groups of mice were similar on the first day of
leptin or saline injection (Figure 4B), improvement of leptin
sensitivity is suggested to be a direct effect of PAI-1 inhibition
rather than a secondary effect reflecting suppressed weight gain.
Thus, TM5441 treatment primarily improves leptin sensitivity in
HFD-fed mice, thereby suppressing weight gain.
We next investigated the effect of TM5441 on leptin receptor
signaling in the hypothalamus in HFD-fed mice (Experimental
procedure 9). Leptin binds to the leptin receptor on
proopiomelanocortin (POMC) neurons in the arcuate nucleus
(ARC) to directly activate and induce POMC expression, while
exerting an inhibitory effect on agouti-related peptide (AgRP)/
neuropeptide Y (NPY) neurons (Timper and Bruning, 2017). We
therefore studied ARC of HFD-WT-TM5441-Leptin, HFD-WT-
Control-Leptin, HFD-WT-TM5441-Saline, and HFD-WT-
Control-Saline mice fed HFD for 1 week, which had similar
body weight (Figure 4D). Expression levels of these
neuropeptides were examined in the ARC of mice 4 h after
leptin administration. Although mRNA expression levels of agrp
and npy showed no alterations in these four groups, Pomc
expression was significantly increased in HFD-WT-TM5441-
Leptin mice as compared to WT-Control-Leptin mice (HFD-
WT-Control-Leptin mice 1.01 ± 0.12 vs HFD-WT-TM5441-
Leptin mice 1.47 ± 0.23, P = 0.031) (Figure 4E). We further
studied the effect of TM5441 on expressions of thermogenesis-
related genes, such as ucp1, dio2, cidea, and prdm16, in brown
adipose tissue (BAT) (Experimental procedure 10), because
enhanced leptin signaling in the hypothalamic ARC increases
BAT thermogenesis (Rezai-Zadeh and Munzberg, 2013). After 1
week of HFD with or without TM5441, all of the thermogenesis-
related genes, including ucp 1 (HFD-WT-Control mice 1.00 ±
0.07 vs HFD-WT-TM5441 mice 1.32 ± 0.05, P = 0.002), were
significantly up-regulated by TM5441 treatment (Figure 4F).
These findings, taken together, suggest that administering
TM5441 improves leptin sensitivity in neurons comprising theFrontiers in Pharmacology | www.frontiersin.org 9hypothalamic ARC, thereby activating BAT. Notably, this
improvement was also observed, before suppression of weight
gain became evident. Thus, an underlying mechanism whereby
TM5441 treatment suppresses weight gain is alleviation of
hypothalamic leptin resistance induced by HFD.DISCUSSION
In the present study, we identified a previously unknown role of
PAI-1 in body weight regulation. First, under HFD fed
conditions, PAI-1 KO mice gained less body weight, and
significant reduction in food intake preceded weight gain. We
next found that pharmacological inhibition of PAI-1 during
HFD feeding also suppressed HFD-induced body weight gain.
TM5441 did not suppress HFD-induced body weight gain in
PAI-1-KO mice, indicating that PAI-1 inhibition per se is the
mechanism underlying suppression of HFD-induced body
weight gain. Finally, we found that leptin sensitivity was
improved by TM5441 treatment. Therefore, the mechanism
underlying weight gain suppression by PAI-1 inhibition
involves alleviation of leptin resistance. Collectively, these
observations indicate that PAI-1 plays a role in aggravating
leptin resistance during obesity development. Therefore, PAI-1
inhibitors may act as leptin sensitizers in states of HFD-induced
obesity. Thus, inhibition of PAI-1 activity is a potential
therapeutic strategy for fighting obesity via alleviation of
leptin resistance.
Contrary to HFD fed conditions, neither weight gain nor food
intake was reduced in PAI-1 KO mice under chow fed
conditions. These features might be explained by a difference
in PAI-1 expressions between lean and obese states. PAI-1 is
produced in adipose tissue (Khandekar et al., 2011) and its PAI-1
expression is increased in states of obesity, since several fold
higher pai-1 expressions are seen in adipose tissues of HFD fed
mice than in those of chow fed mice (Wang et al., 2018).
Consistently, elevated PAI-1 levels are seen in both adipose
tissues and plasma obtained from obese mice and humans as
compared to lean controls (Bodary, 2007). Therefore, marked
effects of PAI-1 deficiency or PAI-1 inhibition might not be
observable under chow fed conditions when PAI-1 is
not elevated.
In addition to suppression of body weight gain, PAI-1
deletion and PAI-1 inhibition resulted in improvement of
insulin sensitivity. Because improved insulin sensitivity
secondary to weight loss is a significant contributor to the
improvement and reversal of type 2 diabetes mellitus (T2DM)
(Chaudhry et al., 2016), our findings suggest that PAI-1 might be
involved in the pathophysiology of T2DM and insulin resistance.
HFD-induced leptin resistance is associated with chronic low-
grade inflammation in the hypothalamus (Saltiel, 2016).
Although it remains unclear whether PAI-1 passes through the
blood brain barrier, elevated PAI-1 in the circulation may
exacerbate the hypothalamic inflammation during obesity
development. In addition to this mechanism, PAI-1 which isJune 2020 | Volume 11 | Article 943
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enhancement of hypothalamic inflammation (Jeon et al., 2012).
Increased saturated fatty acids in the periphery reportedly cross
the blood brain barrier and induce inflammatory responses in
hypothalamic neurons, as rapidly as within a few days after HFD
initiation and obviously before substantial weight gain occurs
(Thaler et al., 2012). Thus, fatty acids are considered to be
involved in inducing hypothalamic inflammation. Inflammatory
processes in the hypothalamus reportedly involves activation of
microglia, the tissue-resident macrophages in the brain, which
further secrete inflammatory cytokines, such as tumor necrosis
factor-a, in the hypothalamus (Avalos et al., 2018). PAI-1 might
be another cytokine that contributes to hypothalamic
inflammation, because resident cells in the brain including
microglia reportedly produce PAI-1 (Arnoldussen et al., 2014).
In addition, microglial migration is considered to be enhanced by
autocrine or paracrine of PAI-1, because (i) PAI-1 treatment
promoted migration of microglial cell lines in vitro in a dose-
dependent manner, (ii) PAI-1 exerted these effects in vitro by
targeting low density lipoprotein receptor-related protein-1 in
microglial cell lines, and (iii) exogenous PAI-1 injection actually
promoted microglial migration in vivo (Jeon et al., 2012). Thus,
HFD feeding might initiate hypothalamic inflammation, and then
induce activation andmigration of microglia, which in turn results
in autocrine or paracrine secretion of PAI-1, leading to further
enhancement of microglial migration and hypothalamic
inflammation, thereby forming a vicious cycle. Importantly,
TM5441 has already been shown to penetrate the blood brain
barrier and thereby reach the central nervous system (Pelisch
et al., 2015). This mechanismmay explain why PAI-1 deletion had
no effect in chow-fed mice (Figures 1A–C), while both PAI-1
deletion (Figures 1D, F) and pharmacological inhibition (Figures
2A, B) exerted profound effects in HFD-fed mice. At present, we
do not have experimental data supporting the presence of chronic
systemic inflammation or hypothalamic local inflammation in
HFD-fed control mice. Future studies focusing on HFD-induced
hypothalamic inflammation, especially whether such
inflammatory responses are affected by PAI-deletion or TM5441
treatment, might more precisely unveil molecular mechanism by
which PAI-1 modulates HFD-induced leptin resistance.
Leptin decreases body weight by inhibiting food intake as well
as by promoting energy expenditure by acting on hypothalamic
nuclei (Timper and Bruning, 2017). Among these nuclei, the
ARC is the key area for the regulation of feeding behavior (Saltiel,
2016). In this study, decreased plasma leptin concentrations were
observed in HFD-WT-TM5411 mice 7 days after TM 5411
treatment (Figure 4A), while the body weight of HFD-WT-
TM5411 mice was not changed at this time-point (day 7 of
Figure 2B). If leptin sensitivity is not changed by TM5441
treatment, decreased leptin levels in these mice would
theoretically induce further body weight gain. However, no
induction of body weight gain was observed in HFD-WT-
TM5411 mice. Instead, weight gain was actually suppressed.
These findings suggest that improvement of leptin sensitivityFrontiers in Pharmacology | www.frontiersin.org 10primarily occurred in HFD-WT-TM5411 mice and led to
attenuation of their body weight gain. Expectedly, leptin
tolerance tests, which had been performed before body weight
differences became evident, directly demonstrated leptin
sensitivity to be markedly improved by TM5411 treatment
(Figures 4B, C). TM5411 treatment significantly increased
POMC expressions in ARC after leptin loading. In addition,
genetic deletion of PAI-1 suppressed food intake before body
weight differences became evident under HFD-fed conditions.
These findings, taken together, suggest that inhibition of PAI-1
activity attenuates hypothalamic leptin resistance induced by
HFD feeding, thereby inducing body weight reduction. This
mechanism, alleviation of leptin resistance, might be ideal for
suppressing weight gain without exerting adverse effects, such as
hypophagia once the individual has returned to a lean state and
leptin resistance has disappeared. This concept is likely
supported by results indicating that even total PAI-1 deficiency
did not affect energy metabolism in chow-fed mice that were
non-obese and leptin-sensitive (Figures 1A–C).
Seven drugs are currently approved by the U.S. Food and
Drug Administration for treating obesity (Saltiel, 2016).
However, all of these drugs were reported to have adverse
effects limiting their usefulness, particularly because most
reduced caloric intake by targeting neurons that control not
only appetite but also sleep and wakefulness, drug dependence,
and other reward systems (Saltiel, 2016). None of these drugs
directly target the leptin sensing systems nor do they primarily
alleviate leptin resistance. Strategies for overcoming leptin
resistance are very limited even in animal models; only those
that have focused on (i) development of protein tyrosine
phosphatase inhibitors to increase the leptin-induced signal
transducer and activator of transcription 3 signaling (Loh
et al., 2011) or (ii) targeting of melanocortin pathways, a
downstream target of POMC neurons (Pierroz et al., 2002),
have been proposed. Therefore, pharmacological inhibition of
PAI-1 activity might emerge as a novel, promising and safe
strategy for suppressing body weight gain, if clinical trials
demonstrate TM5441 to be both effective and safe in humans.CONCLUSION
We have demonstrated a novel role of PAI-1 in exacerbating
hypothalamic leptin resistance, resulting in HFD-induced
obesity. Furthermore, we discovered a novel beneficial effect of
PAI-1 inhibitor treatment, i.e. improved leptin sensitivity, in mice
with HFD-induced obesity. Drugs with this mechanism of action
might revolutionize therapeutic approaches to obesity worldwide.DATA AVAILABILITY STATEMENT
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